lymphoid cancer
Adaptive Biotechnologies, BeiGene Partner for Lymphoid Malignancy Drug Development
Adaptive’s ClonoSeq assay will be used to assess MRD across BeiGene’s pipeline of treatments for patients with lymphoid malignancies.
Adaptive Bio Receives NY State Approval for ClonoSeq in B Cell Cancers
The regulatory approval means that the assay for minimal residual disease is available to monitor B cell blood cancers in patients in all 50 states.
New Molecular Subtypes of Diffuse Large B Cell Lymphoma Identified
An exome- and expression-based analysis of 304 DLBCL cases led to five molecular subtypes, offering insights into disease pathogenesis and treatment outcomes.
British Columbia Cancer Agency Funded $9.5M for Personalized Cancer Project
NEW YORK (GenomeWeb News) – Investigators at the BC Cancer Agency in British Columbia have reeled in an infusion of C$10 million (US$9.5 million) in funding from regional and national partners to fund an effort to use genome sequencing to personalize treatments for patients with lymphoid cancers.